Prospective Study
Copyright ©The Author(s) 2024.
World J Gastrointest Pharmacol Ther. May 28, 2024; 15(3): 90757
Published online May 28, 2024. doi: 10.4292/wjgpt.v15.i3.90757
Figure 4
Full Size Figure Download Figure
Figure 4 Change in paired bloating scores from baseline to week 4 of GASTRAP® DIRECT treatment (visit 1 to visit 3). A: Change in paired bloating scores; B: Abdominal bloating scores (0–10); C: Patient responders (delta > 30%) with respect to bloating. cP < 0.001. W: Weeks.
  • Citation: Talbodec N, Le Roy P, Fournier P, Lesage B, Lepoutre E, Castex F, Godchaux JM, Vandeville L, Bismuth B, Lesage X, Bayart P, Genin M, Rousseaux C, Maquet V, Modica S, Desreumaux P, Valibouze C. Efficacy and tolerability of chitin-glucan combined with simethicone (GASTRAP® DIRECT) in irritable bowel syndrome: A prospective, open-label, multicenter study. World J Gastrointest Pharmacol Ther 2024; 15(3): 90757
  • URL: https://www.wjgnet.com/2150-5349/full/v15/i3/90757.htm
  • DOI: https://dx.doi.org/10.4292/wjgpt.v15.i3.90757